Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.78 |
| ▸ | KDR | P35968 | 13/20 | 0.77 |
| ▸ | CSK | P41240 | 3/20 | 0.77 |
| ▸ | TEK | Q02763 | 3/20 | 0.77 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.77 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | KIF5B | P33176 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214679 | 0.93 | SRC (0.80) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL3196191 | 0.88 | SRC (1.00) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL5215259 | 0.87 | KDR (0.75) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL5215250 | 0.87 | KDR (0.75) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL3210014 | 0.87 | SRC (1.00) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL29432584 | 0.87 | SRC (1.00) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL5218186 | 0.86 | SRC (0.92) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL6583527 | 0.86 | KDR (0.74) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL5216847 | 0.85 | SRC (0.87) | SRCKDRCSKTEKEPHB4 | |
| Hydrochloric Acid SCHEMBL5217413 | 0.85 | KDR (0.73) | SRCKDRCSKTEKEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | SRC 3644/4885KDR 2580/4885CSK 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.